November 4, 2022 – George W. Rozakis, MD, and Brian Bakke Ph.D. pioneered a groundbreaking solution that promises to be a game changer for people currently suffering from Age-related Macular Degeneration. Their latest work – the Macular Program, is the product of 12 years of trailblazing rigorous research and clinical development, which eventually birthed a new and effective way to treat Dry & Wet Macular Degeneration.
Age-related Macular Degeneration (AMD) is a medical condition that typically affects individuals 55 and older, by compromising their ability to see fine details, regardless of how close or far they are from the object. Thought to be the leading cause of vision loss in the United States, this progressive condition is subdivided into two types/stages; Dry Macular Degeneration which accounts for 80% of AMD suffers, and the more severe but less common Wet Macular Degeneration which makes patients lose vision faster.
Dry AMD occurs when parts of the macula get thinner and degenerate with age and tiny clumps of protein and cholesterol called ‘drusen’ grow, leading to the slow loss of central vision. Wet AMD involves the growth of new, abnormal blood vessels under the retina, which sometimes leak blood and other fluids that cause scarring of the macula.
There are numerous risk factors for AMD, which can greatly impact the severity and rate of progression of this incurable disease. Until now, the only recourse for patients with AMD are one size fits all AREDS vitamins, which only provide a 5.9% chance of slowing vision loss. The grim reality is that millions of AMD patients are simply waiting for their vision to get worse, despite the best efforts and intentions of their eye doctor.
Through the Macular Program, Dr. Rozakis and Dr. Bakke are rewriting the treatment procedure for AMD and giving sufferers of the condition more than just a fighting chance. Their groundbreaking solution is uniquely tailored to each patient and works by targeting the underlying root cause of the condition.
In 2021 participants in the Macular Program completed a study evaluating the effectiveness of their personalized care plans. At the conclusion of the 9-month study, 60% (42/70) of Wet AMD patients reported improvement in visual acuity and/or a reduction in the frequency of anti-VEGF injections, while 48% (44/92) of dry AMD patients reported improvement in visual acuity during the study period while the majority of the remaining patients remained stable.
Video Link: https://www.youtube.com/watch?v=R3GzQu0yVfo
If you would like to determine whether you are a candidate for the Macular Program we invite you to connect with us at macularprogram.com to learn more about how we can help you more effectively manage this progressive, life-altering condition.
Company Name: Northeastern Eye Center
Contact Person: Christina Cabral
Email: Send Email
Address:842 Beach Road
State: OH 44107
Country: United States